# Turning Point Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/turning-point-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.tptherapeutics.com
- Total disclosed funding: $45M
- Latest round: Series C (May 23, 2017)
- Investors on record: 5

## About

Turning Point Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on targeted therapies to improve cancer treatment outcomes.Founded in 2013 and headquartered in San Diego, US, Turning Point Therapeutics, Inc. focuses on developing novel cancer therapeutics with a specific emphasis on targeted treatments. The company has raised USD 4.1 bn in total funding, with its most recent funding round being a Trade Sale completed in August 2022, acquiring the company by Bristol-Myers Squibb Company. CEO Athena Countouriotis leads the firm, which has engaged in 10 deals since its inception.Turning Point Therapeutics, Inc. specializes in creating targeted therapies for cancer treatment, utilizing a range of innovative biological and small molecule therapies. Their product offerings aim to improve patient outcomes by enabling precise treatment options that directly target cancer cells, thereby enhancing the efficacy of cancer treatment and providing healthcare professionals with advanced therapeutic solutions in oncology.In 2021, Turning Point Therapeutics, Inc. reported a revenue of USD 30.83 mn, while experiencing an EBITDA loss of USD 229.91 mn for the same year.Looking forward, Turning Point Therapeutics, Inc. is strategically focused on expanding its product pipeline and geographic presence. The company plans to utilize its recent funding from Bristol-Myers Squibb to enhance its development of targeted oncology therapies and explore new markets for commercial expansion. This includes leveraging its acquisition by Bristol-Myers Squibb to facilitate entry into additional global regions, aiming to increase accessibility and availability of its innovative treatments.

## Funding rounds

- Series C, May 23, 2017, $45M — OrbiMed Advisors, SR One, Lilly Asia Ventures, Cormorant Asset Management, SV Tech Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- SV Tech Ventures (https://capitalatlas.ai/funds/sv-tech-ventures) — Series C